BioLife Solutions Inc
NASDAQ:BLFS
EV/EBIT
Enterprise Value to EBIT
Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.
Market Cap | EV/EBIT | ||||
---|---|---|---|---|---|
US |
BioLife Solutions Inc
NASDAQ:BLFS
|
801.5m USD | -14.2 | ||
JP |
Hoya Corp
TSE:7741
|
6.3T JPY | 28.4 | ||
CH |
Alcon AG
SIX:ALC
|
36B CHF | 36.8 | ||
DK |
Coloplast A/S
CSE:COLO B
|
190B DKK | 29.8 | ||
US |
Align Technology Inc
NASDAQ:ALGN
|
21B USD | 30.3 | ||
US |
Cooper Companies Inc
NYSE:COO
|
18.9B USD | 40.1 | ||
KR |
H
|
HLB Inc
KOSDAQ:028300
|
13.7T KRW | -109.1 | |
CN |
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
60.4B CNY | 32 | ||
UK |
ConvaTec Group PLC
LSE:CTEC
|
5.4B GBP | 50.9 | ||
US |
DENTSPLY SIRONA Inc
NASDAQ:XRAY
|
5.8B USD | 25.9 | ||
CA |
B
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.3B USD | 43 |
EV/EBIT Forward Multiples
Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.